We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Determinant Governs H Pylori Behavior

By Biotechdaily staff writers
Posted on 02 Jun 2006
Researchers have found that the ulcer-causing bacteria Helicobacter pylori requires a specific gene to be able to follow the pH gradient from the acidic reaches of the stomach to the more alkaline region of the gastric mucosa. More...
Mutants lacking this gene were unable to infect a line of susceptible mice.

Investigators at the University of Virginia (Charlottesville, USA) used a microscope slide-based pH gradient assay and video data collection system to document pH-tactic behavior. In response to hydrochloric acid, H pylori changed its swimming pattern from straight-line random swimming to arcing or circular patterns that moved the motile population away from the strong acid. Bacteria in more-alkaline regions did not swim toward the acid.

To identify the chemoreceptors responsible for the transduction of pH-tactic signals, genetic engineering was used to construct mutations in each of the four known chemoreceptor genes (tlpA, tlpB, tlpC, and tlpD) in H pylori strain SS1 and a motile variant of strain KE26695. Results of studies with these mutant strains published in the April 2006 edition of the Journal of Bacteriology revealed that only tlpB mutants were defective for pH taxis.

While tlpA, tlpC, and tlpD mutants were able to colonize mice to near wild-type levels, tlpB mutants failed to infect a line of highly permissive C57BL/6 mice. Replacement of tlpB restored both pH taxis and infectivity for mice.

"Because pH sensing ability is essential for colonization and persistence in the stomach lining tissue, the tlpB pH receptor might represent a novel target for the development of treatments that can interfere with this behavior,” said senior author Dr. Paul S. Hoffman, professor of infectious diseases at the University of Virginia. "H pylori infections occur most often in developing countries that cannot afford the cost of miracle drugs. Perhaps a narrow-spectrum drug designed to block the chemoreceptor would be less expensive to develop.”



Related Links:
University of Virginia

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
POC Immunoassay Analyzer
Procise DX
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.